Both, the increase in Tau protein levels as well as its hyper-phosphorylation in the cerebrospinal fluid (CSF) along with lower Aβ1–42 (Aβ42) has shown higher sensitivity and specificity in discriminating AD from controls [6,7]. This evidence concerns the gene MAPT and Alzheimer disease.